Boehringer Ingelheim

BOEHRINGER INGELHEIM NEWSROOM (8 press releases)

Advanced Filtering & Sorting Options:

Archive by Year: All 2025 2024 2023 2019 2018 2017 2016 2015 2014 2013 2012

Boehringer Ingelheim and China Southeast University Institute of Life Sciences to develop new treatment approaches for hearing loss

PRESS RELEASE -- 1, December 2016

360 million people worldwide suffer from disabling hearing loss with no effective treatment available New collaboration with China Southeast University is part of the Research Beyond Borders (RBB) initiative, which aims to explore emerging science within and beyond Boehringer Ingelheim’s … Read the full press release →

University of Liverpool identifies the mechanism causing resistance of pancreatic cancer cells to chemotherapy

PRESS RELEASE -- 25, November 2016

LIVERPOOL, 25-Nov-2016 — /EuropaWire/ — A pioneering University of Liverpool research team have published a study that identifies the mechanism in the human body that causes resistance of pancreatic cancer cells to chemotherapy. Pancreatic cancer is one of the leading … Read the full press release →

Sanofi welcomes Alan Main as EVP Consumer HealthCare

PRESS RELEASE -- 4, October 2016

PARIS, 04-Oct-2016 — /EuropaWire/ — Sanofi today announced the appointment of Alan Main as Executive Vice President Consumer HealthCare, effective October 1st, 2016. Mr. Main will be a member of the Executive Committee and lead a newly created Consumer Healthcare … Read the full press release →

Boehringer Ingelheim: Risankizumab (formerly BI 655066) shown to be more effective than placebo in patients with moderately-to-severely active Crohn’s disease

PRESS RELEASE -- 27, May 2016

After 12 weeks, approximately twice as many patients with moderate-to-severe Crohn’s disease, the majority of whom had previously failed treatment with one or more TNF antagonists,  achieved clinical remission with risankizumab compared with placebo1 Endoscopic remission was achieved in 15% … Read the full press release →

Boehringer Ingelheim: EU grants marketing authorisation for Giotrif® for the treatment of patients with advanced squamous cell carcinoma (SqCC) of the lung

PRESS RELEASE -- 8, April 2016

• Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases.1,2 • Approval of Giotrif® is based on results of the LUX-Lung 8 study, … Read the full press release →

Boehringer Ingelheim’s Interim Phase III Data: 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran in all patients evaluated

PRESS RELEASE -- 8, April 2016

• A single 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran in all patients evaluated • Results based on analyses of high-risk patients from RE-VERSE AD™ study • Data presented at ACC 2016 Scientific Session and Expo … Read the full press release →

26 research projects related to Porcine Circovirus Type 2 (PCV2) infection funded by Boehringer Ingelheim Animal Health over the past 9 years

PRESS RELEASE -- 3, March 2016

Ingelheim, Germany, 03-Mar-2016 — /EuropaWire/ — For the ninth time, Boehringer Ingelheim Animal Health has funded independent European research projects related to Porcine Circovirus Type 2 (PCV2) infection and associated diseases. Over the past nine years, 26 research projects have been … Read the full press release →

Boehringer Ingelheim announces results of LUX-Lung 7 trial for treatment of patients with advanced non-small cell lung cancer with EGFR mutations

PRESS RELEASE -- 1, February 2016

• Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib superior in reducing the risk of lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib1 • More patients on afatinib were free of … Read the full press release →